Blood pressure and risk of cardiovascular diseases in type 2 diabetes: Further findings from the Swedish National Diabetes Register (NDR-BP II)

Journal of Hypertension

Volumn 30, Issue 10, 2012, Pages 2020-2030

  Cederholm, Jan ^a   Gudbjörnsdottir, Soffia ^b   Eliasson, Björn ^b   Zethelius, Björn ^c   Eeg Olofsson, Katarina ^b   Nilsson, Peter M ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

cardiovascular diseases; diabetes; hypertension; myocardial infarction; register; stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGISTER; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 84866562620     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283577bdf     Document Type: Article

References (31)

1. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
2. Cederholm J, Gudbjörnsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM, on behalf of the NDR. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. J Hypertens 2010; 28:2026-2035.
3. Cederholm J, Zethelius B, Eliasson B, Gudbjörnsdottir S, Nilsson PM. Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression. J Hypertens 2012; 30:235-237.
4. Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Eliasson B, Gudbjörnsdottir S, on behalf of the Swedish National Diabetes Register. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diab Res Clin Pract 2009; 86:74-81.
5. Nilsson PM, Cederholm J, Zethelius B, Eliasson B, Eeg-Olofsson K, Gudbjörnsdottir S. Trends in blood pressure control in patients with type 2 diabetes-Data from the Swedish National Diabetes Register (NDR). Blood Pressure 2011; 20:348-354.
6. Nilsson PM, Cederholm J. Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care 2011; 34 (Suppl 2):S109-S113.
7. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Wiedmeyer HM, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50:166-174.
8. Merlo J, Lindblad U, Pessah-Rasmussen H, Hedblad B, Rastam J, Isacsson SO, Rastam L, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000; 16:235-243.
9. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
10. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al., ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
11. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al., ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
12. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
13. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
15. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Zanchetti A, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
16. SHEP Collaborative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
17. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 2010; 31:2837-2840.
18. Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB. Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens 2012; DOI:10.1097/HJH.0b013e3283516499.
19. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893.
20. Redon J, Mancia G, Sleight P, Schumacher H, Fagard R, Yusuf S, et al., ONTARGET investigators. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ongoing telmisartan alone and in combination with Ramipril Global Endpoint Trial study). J Am Coll Cardiol 2012; 59:74-83.
21. Bangalore S, Messerli FH, Wun C-C, Zuckerman AL, DeMicco D, Kostis JB, et al., Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur Heart J 2010; 31:2897-2908.
22. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, for the PROVE IT-TIMI 22 trial investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: relationship of blood pressure and cardiovascular events in the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 Trial. Circulation 2010; 122:2142-2151.
23. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Holman RR, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
24. Kai H, Ueno T, Kimura T, Adachi H, Furukawa Y, Kita T, et al., On behalf of CREDO-Kyoto investigators. Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. J Hypertens 2011; 29:1889-1896.
25. Kotsis V, Grassi G. J-curve for DBP and cardiovascular mortality in coronaryartery disease patients: myth or reality. J Hypertens 2011; 29:1854-1856.
26. Franklin SS. Isolated systolic hypertension and the J-curve of cardiovascular disease risk. Artery Res 2010; 4:1-6.
27. Heinzl H, Kaider A. Manual for the SAS-Macro RCS (Version 2.0). Technical Report KB 1-96. Wien, Austria: Institut für Medizinische Computerwissenschaften, Abteilung für Klinische Biometrie, Universität Wien; 1996.
28. Anderson RJ, Bahn G, Moritz TE, Kaufman D, Abraira C, Duckworth W, for the VADT study group. Blood pressure and cardiovascular disease risk in the veterans affairs diabetes trial. Diabetes Care 2011; 34:34-38.
29. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep 2011; 13:452-455.
30. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose. Observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123:2799-2810.
31. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens 2011; 29:1253-1269.